Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Vipshop Holdings Ltd - ADR (VIPS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Vipshop Holdings Ltd - ADR — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $224.04 (market cap $29.60B), while Vipshop Holdings Ltd - ADR trades at $14.46 (market cap $7.20B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 4.1× Vipshop Holdings Ltd - ADR's market cap, and Vipshop Holdings Ltd - ADR pays a 4.14% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | VIPS | |
|---|---|---|
Market Cap | $29.60B | $7.20B |
Sector | Health | Consumer Cyclical |
52-Week High | $491.22 | $20.68 |
52-Week Low | $205.48 | $12.92 |
Enterprise Value | $27.56B | $3.76B |
Dividend Yield | — | 4.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $216.98, down 1.01% with bearish technical signals. The company shows strong revenue growth from $1.0B in 2022 to $3.7B in 2025, turning profitable with $314M net income. However, recent Q2 2026 earnings missed expectations, and multiple law firms are investigating potential securities fraud. Analyst consensus remains bullish with a $370.07 price target despite recent volatility.
The stock faces near-term pressure from legal investigations and earnings volatility, but strong fundamentals and analyst support suggest long-term potential. Key risks include legal outcomes and execution on growth targets, while the 71% upside to consensus target offers opportunity if the company can maintain its revenue trajectory.
Vipshop (VIPS) trades at $15.41, down 1.72% on the day, with a bullish technical signal from moving averages. The stock shows attractive valuation metrics, including a P/E of 6.79 and P/S of 0.48, while maintaining solid profitability with a net income margin of 7.07%. Recent Q1 2026 earnings met expectations, and the company is pursuing growth through an outlet store REIT strategy, as reported by Seeking Alpha on May 22, 2026.
The outlook is cautiously positive, supported by low valuations and analyst consensus, but risks include revenue stagnation and macroeconomic pressures in China. Near-term catalysts depend on Q2 2026 earnings beating the $0.62 EPS estimate to reaffirm growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Vipshop Holdings Ltd - ADR
Vipshop Holdings Ltd is an online discount retailer for brands in China. The company offers branded products to consumers in China through flash sales on its vipshop.com, vip.com and lefeng.com websites. Flash sales represent an online retail format combining the advantages of e-commerce and discount sales through selling a finite quantity of discounted products or services online for a limited period of time. It deals in a wide range of products and services for consumers specializing in branded cosmetics, apparel, healthcare products, food and other consumer products. Its operating segment includes Vip.com and Shan Shan Outlets. The company generates maximum revenue from Vip.com segment.
Read more on VIPS →
